Your browser doesn't support javascript.
loading
Can composite digital monitoring biomarkers come of age? A framework for utilization.
Kovalchick, Christopher; Sirkar, Rhea; Regele, Oliver B; Kourtis, Lampros C; Schiller, Marie; Wolpert, Howard; Alden, Rhett G; Jones, Graham B; Wright, Justin M.
Afiliação
  • Kovalchick C; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Sirkar R; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Regele OB; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Kourtis LC; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Schiller M; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Wolpert H; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Alden RG; Eli Lilly Innovation Center, Cambridge, MA, USA.
  • Jones GB; Clinical & Translational Science Institute, Tufts University Medical Center, Boston, MA, USA.
  • Wright JM; Eli Lilly Innovation Center, Cambridge, MA, USA.
J Clin Transl Sci ; 1(6): 373-380, 2017 Dec.
Article em En | MEDLINE | ID: mdl-29707260
ABSTRACT

INTRODUCTION:

The application of digital monitoring biomarkers in health, wellness and disease management is reviewed. Harnessing the near limitless capacity of these approaches in the managed healthcare continuum will benefit from a systems-based architecture which presents data quality, quantity, and ease of capture within a decision-making dashboard.

METHODS:

A framework was developed which stratifies key components and advances the concept of contextualized biomarkers. The framework codifies how direct, indirect, composite, and contextualized composite data can drive innovation for the application of digital biomarkers in healthcare.

RESULTS:

The de novo framework implies consideration of physiological, behavioral, and environmental factors in the context of biomarker capture and analysis. Application in disease and wellness is highlighted, and incorporation in clinical feedback loops and closed-loop systems is illustrated.

CONCLUSIONS:

The study of contextualized biomarkers has the potential to offer rich and insightful data for clinical decision making. Moreover, advancement of the field will benefit from innovation at the intersection of medicine, engineering, and science. Technological developments in this dynamic field will thus fuel its logical evolution guided by inputs from patients, physicians, healthcare providers, end-payors, actuarists, medical device manufacturers, and drug companies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Clin Transl Sci Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Clin Transl Sci Ano de publicação: 2017 Tipo de documento: Article